# AUY922 for Advanced ALK-positive NSCLC

> **NCT01752400** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 6 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AUY922

## Key facts

- **NCT ID:** NCT01752400
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-06
- **Final completion:** 2017-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752400, "AUY922 for Advanced ALK-positive NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01752400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*